Pre-Clinical Study | Amgevita In Vitro Studies | Amgen

WHAT'S BEHIND amgevita®


Similar to Humira® in non-clinical and in vitro studies

AMGEVITA® was shown to be bioequivalent to Humira® for toxicokinetic parameters, with no unexpected toxicity observed with either therapy.1,2
Similar toxicokinetic parameters between AMGEVITA® and Humira® after single and repeated weekly dosing in male and female cynomolgus monkeys1,2*
  • In analytical characterization studies, similarity was also shown for the primary mechanisms of action/potency1
*A comparative toxicology study in male and female cynomolgus monkeys receiving 157 mg/kg/week doses of AMGEVITA® and Humira®.
  1. AMGEVITA® European Public Assement Report, January 2017.
  2. ABP 501: Background information for the arthritis advisory committee. Submitted to the FDA by Amgen, July 2016.

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.